Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As long as it isn't a head and shoulders pattern that takes us back to $1.00, that would SUCK!
I believe since TChaunceys last post, HENC has filed regulatory documents and there was a private placement or shares issued for some cash. They aren't just letting it die, but will probably not initiate anything until nearing the deadlines.
I forgot that was today. Was it live streamed or do you know if there is a link to re-play?
Over the past three green closes, all the buying pressure has come in the hour or minutes before the close with a mid-day dip. Just something to watch for, volume has been minimal though. Some of us own share totals that are greater than volume on some of these days.
It does mention Prurisol. Says data expected in Q2.
They have the cash already, don't they? I believe something to the tune of $50m.
It is going to be a long painful road, I agree. There will be a lot of ups and downs.
I really dislike that they limit the CC to 1 hour now, and only take questions if time permits.
I've been expecting it to hit $2 for sometime now just looking at the chart, minus any substantive news of course. I also expected a bigger bounce once it hit, so you may be right. Lucky for me I'm not trading it and just sitting for a while I guess, still gut churning.
Not sure how long this has been there, but just browsing Holloman Corp (Parent Co.) site this morning and saw this dot over Cooper with no details below.
https://www.hollomancorp.com/locations/
It's on their RADAR.
Government covers my prescriptions/purchase via CannTrust. I think it is very popular for Veterans Affairs in Canada to cover most vets using this company. I didn't know they were public until you posted that.
I'm not 100% sure, but unless there is a THC limit on the hemp legally produced, then XXII technology may not be important.
Thanks TC, I know that I have been waiting on this post for a while.
Ask is at 6 cents, trades pretty thin. Good sign for if we ever hear a peep from either company.
Hope it's not anyone on this board purchasing today, that would be nice. Few more weeks of 75% days and I will be back to my original buy in price!
I have to be honest, I look forward to when you post on here like you used to. Always had very good insights and contributed 95% of the relevant information to this board. I hope that within the next couple quarters we get a direction from the company, weather it's abandonment of the PEL's or a partner to drill before that January, 10 2019 deadline.
Quick question for people who have tracked a lot of biotech's over the years. If a deal is announced for $25m upfront and milestones of up to $200m, has the market usually valuated a company at the $200m soon after? Or is there usually little correlation?
Next hole is supposed to be drilled within 10 months, think it will happen?
I too increased my position over the last two years, based on the language in the last PR. I have never had a conversation with management though. If they run a multi-billion dollar company, I'm sure they are effevtive enough to do this if they want to.
We can expect to hear more on the FDA plan for reduction within the coming weeks.
The volume is far too low for it to be a leak. It's nice to see that with no selling pressure that very low volume can move it so much though.
Is that a 800K share transaction? Hmmm.
Is the CC today with earnings? If so does anyone have a link?
You forgot, 'know when to hold them'.
I didn't get my Christmas card this year, or year in review. Did anyone?
Over 200k volume, not a bad start. But when you own that many or more shares it doesn't seem like much. Or when you realise that it is under $4,000 in volume.
Is anyone at the conference from here? i think it just started right?
I can't find the agreement anymore. I don't believe until 2019 to 2021, each PEL. That's drilling anyways, I think 3D is due every year.
Some trades going on, I sent an email asking for some info. Holloman never responds but maybe Claren will.
I didn't know that, I only posted what I read. Thanks.
The form is out, I'm long IPIX for 5 years. Stop slamming everyone.
Bertolino sold 240,000 shares.
With WTI above $65 it would be interesting to see if HENC decides to do anything. $60 was there target for stabilization before doing anything so...
100k sell, buy today. Just hope they don't delist and turn company private.
Kevetrin’s Effect on the p53 Signaling Pathway in a Broader Scientific Context
Kevetrin
The Company has provided an update on Kevetrin -- its p53-modulating, anti-cancer drug candidate -- currently being studied in a Phase 2a trial for platinum-resistant/refractory Ovarian Cancer (OC). Earlier, the company successfully completed a Phase 1 study in Advanced Solid Tumors, which was conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Centers.
A primary goal of the Phase 2a OC study is to evaluate changes in biomarkers and molecular signatures related to cell proliferation and cell death. In particular, the Company would like to better understand how Kevetrin affects p53 -- a tumor suppressor protein produced by the TP53 gene and common to most animals -- via pathway analyses of RNA and protein biomarkers collected from patient tissue and blood samples.
Preliminary results show modulation of the p53 protein, as well the activated form of the protein, phospho-p53, in response to the administration of Kevetrin. Pathways analyses also point to concomitant cell cycle modulation at the level of gene expression. Importantly, these data directly support Kevetrin's ability, in ovarian cancer patient tumors, to affect p53 and associated molecular pathways -- the central gene signaling network involved in regulating cell growth and the cell cycle, helping to prevent cancer.
p53 as the Master Switch in Controlling Cancer Suppression
Referred to as the "master switch" given its central role in regulating the highly distributed gene signaling network controlling cancer, arguably there is "no gene more important" than p53: "The loss of TP53 as signature driver of human cancers is indisputable." It is the most "scrutinized" gene of all time (p53 in a scientific context); toward cracking p53, on average, approximately two p53-related research papers are published each day.
A 2016 article, “Targeting Mutant p53 in Cancer: A Long Road to Precision Therapy,” excerpted below, reinforces the importance of performing pathway analysis of the kind Innovation research staff currently are engaged in -- toward better understanding cell cycle and cell death regulation in relation to Kevetrin's ability to modulate the p53 pathway in cancer.
"Recent studies indicate that successful strategies to extract core aspects of mutant p53 oncogenic potential and to identify unique tumor dependencies entail the superimposition of large-scale analyses performed in multiple experimental systems, together with a mindful use of animal models. This will hopefully soon lead to the long-awaited inclusion of mutant p53 as an actionable target of clinical antitumor therapies."
A 2017 article, "Cancer in the Crosshairs," on research out of UC Santa Cruz, makes a similar point, highlighting the importance of the Retinoblastoma (Rb) tumor suppressor protein -- a central player in many signaling pathways disrupted in cancer cells. In pre-clinical work, Kevetrin was shown to target the Rb-E2F signaling pathway (see the 2012 AACR abstract and poster, pdf).
Kevetrin Oral Formulation Plans
Running in parallel to the p53 molecular pathway mapping efforts, the Company has plans to develop Kevetrin as an oral agent (tablet or capsule) that could be dosed multiple times per day. This approach leverages Kevetrin's pharmacokinetic profile and short half-life -- approximately 2 hours, with the drug clearing the body within one day, though on average between 8 and 10 hours. Bioavailability and other lab studies have been encouraging.
Currently there are no approved p53-modulating drugs, much less in pill form. An oral formulation of Kevetrin could, one day, potentially position the drug candidate -- whether as a monotherapy or used in combination with other agents -- as a go-to cancer treatment, which remains the top therapeutic area of focus in Biopharma R&D.
With cancer immunotherapies comprising the majority of oncology-focused drug development efforts (over 2000 agents presently are in the clinical pipeline), by 2022, it is estimated that the top 15 cancer drugs, collectively, will bring in almost $90 billion in sales. Innovative gene therapies, in particular, likely will merit much higher prices than conventional drugs.
Continued...:
http://www.ipharminc.com/new-blog/2017/12/27/kevetrins-effect-on-the-p53-signaling-pathway-in-a-broader-scientific-context
This seems to happen every time, surreal. For some reason I still have hope it turns green by the end of the day, I never learn apparently.
You got that from the conference call? Because I listened to the whole thing and got a very different opinion. Pretty sure Henry said they were going to produce and sell their own VLN and licence the tech.
Is XXII reporting earnings today? I've seen on Google but not from company.
Check your math, or trust the board. It has been 50%(ish).
I share in a lot of frustration on this board. But, comments made that are similar to this are fundamentally wrong.
All three are making over $400K? I'm a long term holder, and I realize Leo put a lot of own money into the company... but I have to agree that that is too much for a company with no revenue or partnerships, especially when SH are suffering. Tsk tsk
HENC Minimum Work Obligation Deadlines:
PEL 112
Acquire 50 square kilometers – 3D seismic
January 10, 2017
PEL 112
Geological and geophysical studies
January 10, 2018
PEL 112
Drill one well
January 10, 2019
PEL 444
Geological and geophysical studies
January 11, 2017
PEL 444
Geological and geophysical studies
January 11, 2018
PEL 444
Geological and geophysical studies
January 11, 2019
PEL 444
Geological and geophysical studies
January 11, 2020
PEL 444
Drill one well
January 11, 2021
Heavy volume? Bahaha. Did money exchanged even exceed $1m? Ha.